Skip to main content
Erschienen in: Journal of Gastroenterology 2/2017

28.06.2016 | Original Article—Liver, Pancreas, and Biliary Tract

The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease

verfasst von: Reona Morio, Hideyuki Hyogo, Masahiro Hatooka, Kei Morio, Hiromi Kan, Tomoki Kobayashi, Tomokazu Kawaoka, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Hidenori Ochi, Yoneda Masayasu, Kazuaki Chayama

Erschienen in: Journal of Gastroenterology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is frequently associated with insulin resistance (IR) and abnormalities in glucose metabolism. Prevalent postprandial hyperinsulinemia along with insulin resistance in NAFLD may lead to hypoglycemia. This study investigated the prevalence of postprandial oxyhypoglycemia in patients with NAFLD.

Methods

The oral glucose tolerance test (OGTT) with 75 g glucose was performed in 375 biopsy-proven NAFLD patients with prior unknown type 2 diabetes mellitus (DM). Serum glucose and insulin levels were measured for 3 h after glucose loading and the clinical parameters were compared.

Results

Normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and DM were observed in 36, 36, and 28 %, respectively. Hypoglycemia (≤70 mg/dL) after 3 h was observed in 14.4 % of all patients. The rate of hypoglycemia was significantly higher in NGT (63 % of NGT) than in IGT (30 % of IGT) and DM (7 % of DM) (P < 0.05). In patients with hypoglycemia, the levels of insulin were significantly higher at 30 and 60 min than those without hypoglycemia (P < 0.05). By multivariate analysis, high-LDL cholesterolemia (P < 0.05), low-HDL cholesterolemia (P < 0.05), and fibrosis (P < 0.05) were significant factors that contributed to hypoglycemia after 3 h on 75 g OGTT.

Conclusions

A relatively higher proportion of NAFLD cases exhibited transient postprandial hypoglycemia after 3 h on OGTT, especially in NAFLD patients with early-stage fibrosis. By performing 75 g OGTT for 3 h, hypoglycemia would be diagnosed earlier and the treatment intervention would decrease the progression of NAFLD and deterioration of glucose metabolism.
Literatur
1.
Zurück zum Zitat Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.CrossRefPubMedPubMedCentral Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49:306–17.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009;41(9):615–25.CrossRefPubMed Petta S, Muratore C, Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis. 2009;41(9):615–25.CrossRefPubMed
3.
Zurück zum Zitat Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9.CrossRefPubMed Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22(6):1714–9.CrossRefPubMed
4.
Zurück zum Zitat Larter CZ, Chitturi S, Heydet D, et al. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25(4):672–90.CrossRefPubMed Larter CZ, Chitturi S, Heydet D, et al. A fresh look at NASH pathogenesis. Part 1: the metabolic movers. J Gastroenterol Hepatol. 2010;25(4):672–90.CrossRefPubMed
5.
Zurück zum Zitat Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26(Suppl 1):163–72.CrossRefPubMed Chitturi S, Wong VW, Farrell G. Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground. J Gastroenterol Hepatol. 2011;26(Suppl 1):163–72.CrossRefPubMed
6.
Zurück zum Zitat Farrel GC, Laeter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.CrossRef Farrel GC, Laeter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43:S99–112.CrossRef
7.
Zurück zum Zitat Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRefPubMed Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRefPubMed
8.
Zurück zum Zitat Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53(5):750–5.CrossRefPubMedPubMedCentral Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut. 2004;53(5):750–5.CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Farrell GC. The liver and the waistline: fifty years of growth. J Gastroenterol Hepatol. 2009;24(Suppl 3):S105–18.CrossRefPubMed Farrell GC. The liver and the waistline: fifty years of growth. J Gastroenterol Hepatol. 2009;24(Suppl 3):S105–18.CrossRefPubMed
10.
Zurück zum Zitat Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16.CrossRefPubMedPubMedCentral Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology. 2011;54(4):1208–16.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Manchanayake J, Chitturi S, Nolan C, et al. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:510–6.CrossRefPubMed Manchanayake J, Chitturi S, Nolan C, et al. Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:510–6.CrossRefPubMed
12.
Zurück zum Zitat Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178–87.CrossRefPubMed Bril F, Lomonaco R, Orsak B, et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology. 2014;59(6):2178–87.CrossRefPubMed
13.
Zurück zum Zitat Rafiq N, Bai C, Fang Y. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8.CrossRefPubMed Rafiq N, Bai C, Fang Y. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol. 2009;7(2):234–8.CrossRefPubMed
14.
Zurück zum Zitat Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224–9.CrossRefPubMed Hossain N, Afendy A, Stepanova M, et al. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(11):1224–9.CrossRefPubMed
15.
Zurück zum Zitat Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRefPubMed Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRefPubMed
16.
Zurück zum Zitat Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRefPubMed Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–54.CrossRefPubMed
17.
Zurück zum Zitat Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8.CrossRefPubMed Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48(3):792–8.CrossRefPubMed
18.
Zurück zum Zitat Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One. 2013;8(11):e76161.CrossRefPubMedPubMedCentral Hashiba M, Ono M, Hyogo H, et al. Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease. PLoS One. 2013;8(11):e76161.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–44.CrossRefPubMed Paradis V, Perlemuter G, Bonvoust F, et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology. 2001;34:738–44.CrossRefPubMed
20.
Zurück zum Zitat Megyesi C, Samols E, Marks V. Glucose tolerance and diabetesin chronic liver disease. Lancet. 1967;18:1051–6.CrossRef Megyesi C, Samols E, Marks V. Glucose tolerance and diabetesin chronic liver disease. Lancet. 1967;18:1051–6.CrossRef
21.
Zurück zum Zitat Hyogo H, Yamagishi S, Maeda S, et al. Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. Dig Liver Dis. 2012;44:935–9.CrossRefPubMed Hyogo H, Yamagishi S, Maeda S, et al. Increased insulinogenic index is an independent determinant of nonalcoholic fatty liver disease activity score in patients with normal glucose tolerance. Dig Liver Dis. 2012;44:935–9.CrossRefPubMed
22.
Zurück zum Zitat Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.CrossRefPubMedPubMedCentral Gaggini M, Morelli M, Buzzigoli E, et al. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–60.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–42.CrossRefPubMed Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia. 2005;48(4):634–42.CrossRefPubMed
24.
Zurück zum Zitat Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84.CrossRefPubMed Nakahara T, Hyogo H, Yoneda M, et al. Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients. J Gastroenterol. 2014;49(11):1477–84.CrossRefPubMed
25.
Zurück zum Zitat Castaldo E, Sabato D, Lauro D, et al. Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One. 2011;6(12):e28312.CrossRefPubMedPubMedCentral Castaldo E, Sabato D, Lauro D, et al. Hypoglycemia assessed by continuous glucose monitoring is associated with preclinical atherosclerosis in individuals with impaired glucose tolerance. PLoS One. 2011;6(12):e28312.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol. 1989;8:107–14.CrossRefPubMed Petrides AS, DeFronzo RA. Glucose and insulin metabolism in cirrhosis. J Hepatol. 1989;8:107–14.CrossRefPubMed
27.
Zurück zum Zitat Kimura Y, Hyogo H, Ishitobi T. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol. 2011;26:517–22.CrossRefPubMed Kimura Y, Hyogo H, Ishitobi T. Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol. 2011;26:517–22.CrossRefPubMed
28.
Zurück zum Zitat Ogata C, Ohmoto-Sekine Y, Tanabe M, et al. Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med. 2014;53(13):1401–6.CrossRefPubMed Ogata C, Ohmoto-Sekine Y, Tanabe M, et al. Prognostic factors for regression from impaired glucose tolerance to normal glucose regulation in Japanese patients with nonalcoholic fatty liver disease. Intern Med. 2014;53(13):1401–6.CrossRefPubMed
29.
Zurück zum Zitat Arya VB, Mohammed Z, Blankenstein O, et al. Hyperinsulinaemic hypoglycaemia. Horm Metab Res. 2014;46(3):157–70 (hyperinsulinaemic).CrossRefPubMed Arya VB, Mohammed Z, Blankenstein O, et al. Hyperinsulinaemic hypoglycaemia. Horm Metab Res. 2014;46(3):157–70 (hyperinsulinaemic).CrossRefPubMed
30.
Zurück zum Zitat Sesti G, Hribal ML, Fiorentino TV, et al. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care. 2014;2(1):e000016.CrossRefPubMedPubMedCentral Sesti G, Hribal ML, Fiorentino TV, et al. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care. 2014;2(1):e000016.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Sugiyama S, Jinnouchi H, Hieshima K, et al. Insulin supersensitivity and normoinsulinaemic hypoglycaemia in uncontrolled type 2 diabetes mellitus: clinical usefulness of 3 h assessment in the 75 g oral glucose tolerance test. BMJ Case Rep. 2014;8:2014. Sugiyama S, Jinnouchi H, Hieshima K, et al. Insulin supersensitivity and normoinsulinaemic hypoglycaemia in uncontrolled type 2 diabetes mellitus: clinical usefulness of 3 h assessment in the 75 g oral glucose tolerance test. BMJ Case Rep. 2014;8:2014.
32.
Zurück zum Zitat Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.CrossRefPubMed
33.
Zurück zum Zitat Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116:1413–9.CrossRefPubMed
34.
Zurück zum Zitat Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Non-alcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed
35.
Zurück zum Zitat Michael MD, Kulkarni RN, Postic C. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87–97.CrossRefPubMed Michael MD, Kulkarni RN, Postic C. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell. 2000;6(1):87–97.CrossRefPubMed
36.
Zurück zum Zitat Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.CrossRefPubMed Tolman KG, Fonseca V, Dalpiaz A, et al. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734–43.CrossRefPubMed
37.
Zurück zum Zitat Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.CrossRefPubMedPubMedCentral Perry RJ, Samuel VT, Petersen KF, et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature. 2014;510(7503):84–91.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Johnson DG, Alberti KG, Faber OK, Binder C. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet. 1977;1(8001):10–3.CrossRefPubMed Johnson DG, Alberti KG, Faber OK, Binder C. Hyperinsulinism of hepatic cirrhosis: diminished degradation or hypersecretion? Lancet. 1977;1(8001):10–3.CrossRefPubMed
39.
Zurück zum Zitat Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12(5):1106–10.CrossRefPubMed Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology. 1990;12(5):1106–10.CrossRefPubMed
40.
Zurück zum Zitat Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23(2):207–15.CrossRefPubMed Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2006;23(2):207–15.CrossRefPubMed
41.
Zurück zum Zitat Sonsuz A, Basaranoglu M, Bilir M, et al. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97(2):495.CrossRefPubMed Sonsuz A, Basaranoglu M, Bilir M, et al. Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2002;97(2):495.CrossRefPubMed
Metadaten
Titel
The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease
verfasst von
Reona Morio
Hideyuki Hyogo
Masahiro Hatooka
Kei Morio
Hiromi Kan
Tomoki Kobayashi
Tomokazu Kawaoka
Masataka Tsuge
Akira Hiramatsu
Michio Imamura
Yoshiiku Kawakami
Hiroshi Aikata
Hidenori Ochi
Yoneda Masayasu
Kazuaki Chayama
Publikationsdatum
28.06.2016
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 2/2017
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-016-1236-7

Weitere Artikel der Ausgabe 2/2017

Journal of Gastroenterology 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.